ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
SARS-CoV2 paper.pdf (1.1 MB)

Insilico Identification of Potential Antivirals and Molecular Dynamics Against SARS-CoV2 Main Protease and RBD of Spike Protein

preprint
submitted on 03.11.2020, 05:36 and posted on 04.11.2020, 05:03 by Vijayakumar Rajendran, Saravanan Kandasamy, Ankita Gupta, Jagannathan Selvaraj, Kukkaler Channappa Shivanandappa

A coronavirus identified as 2019 novel coronavirus (COVID-19) is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan has been declared as a pandemic by the World Health Organization. The virus is predominantly spread from person-to-person mainly through airborne, fomite, contact, and droplet from the infected patients. Also, the lack of definitive treatment is another concern that needs consideration. The novel 2019 SARS-CoV-2 enters the host cell by binding of the viral surface spike glycoprotein (S-protein) to angiotensin-converting enzyme 2 (ACE2). Mpro is a key coronavirus enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus. Considering the importance of these two proteins in the viral infection, these were preferred as a potential drug target against Covid19. In this study, we screened potential antiviral drugs from the Pubchem database and natural antiviral agent quercetin for induced fit docking against these two key proteins. The identified top hit was further evaluated through molecular dynamic simulations. Our results suggest that the antiviral drugs Indinavir and Famciclovir could be a potential drug against Covid19.

History

Email Address of Submitting Author

vijayakumar.thenilgiris@gmail.com

Institution

Indian Institute of Science

Country

India

ORCID For Submitting Author

0000-0002-8332-1859

Declaration of Conflict of Interest

The Authors declare there is no conflict of interest

Exports

Logo branding

Exports